Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPF-501C for bleeding control in cancerous skin ulcers
jRCT2051230016Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Zinc chloride in Cutaneous ulcer, sponsored by Otsuka Pharmaceutical Factory, Inc. Primary endpoints: Presence/absence of oozing bleeding immediately after the 1st use of OPF-501C, Presence/absence of oozing bleeding 1 day after the 1st use of OPF-501C and 8 more. Started Jul 2023; status: completed.
02
Drugs
Zinc chloride
03
Conditions
Cutaneous ulcer
Beyond the preview
Go deeper on jRCT2051230016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230016.